Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 31;16(9):1480-1488.
doi: 10.1093/ckj/sfad068. eCollection 2023 Sep.

Clinical and immunological characteristics of patients with combined anti-glomerular basement membrane disease and IgA nephropathy

Cong-Rong Shen  1   2   3   4   5   6 , Xiao-Yu Jia  1   2   3   4   5 , Zhao Cui  1   2   3   4   5 , Xiao-Juan Yu  1   2   3   4   5 , Ming-Hui Zhao  1   2   3   4   5   7
Affiliations

Clinical and immunological characteristics of patients with combined anti-glomerular basement membrane disease and IgA nephropathy

Cong-Rong Shen et al. Clin Kidney J. .

Abstract

Background: The combination of anti-glomerular basement membrane (GBM) disease and immunoglobulin A nephropathy (IgAN) has been well documented in sporadic cases, but lacks overall assessment in large collections. Herein, we investigated the clinical and immunological characteristics and outcome of this entity.

Methods: Seventy-five consecutive patients with biopsy-proven anti-GBM disease from March 2012 to March 2020 were screened. Among them, patients with concurrent IgAN were identified and enrolled. The control group included biopsied classical anti-GBM patients during the same period, excluding patients with IgAN, other glomerular diseases or tumors, or patients with unavailable blood samples and missing data. Serum IgG and IgA autoantibodies against GBM were detected by enzyme-linked immunosorbent assay, as were circulating IgG subclasses against GBM.

Results: Fifteen patients with combined anti-GBM disease and IgAN were identified, accounting for 20% (15/75) of all patients. Among them, nine were male and six were female, with an average (± standard deviation) age of 46.7 ± 17.3 years. Thirty patients with classical anti-GBM disease were enrolled as controls, with 10 males and 20 females at an average age of 45.4 ± 15.3 years. Patients with combined anti-GBM disease and IgAN had restricted kidney involvement without pulmonary hemorrhage. Compared with classical patients, anti-GBM patients with IgAN presented with significantly lower levels of serum creatinine on diagnosis (6.2 ± 2.9 vs 9.5 ± 5.4 mg/dL, P = .03) and less occurrence of oliguria/anuria (20%, 3/15 vs 57%, 17/30, P = .02), but more urine protein excretion [2.37 (1.48, 5.63) vs 1.11 (0.63, 3.90) g/24 h, P = .01]. They showed better kidney outcome during follow-up (ESKD: 47%, 7/15 vs 80%, 24/30, P = .03). The autoantigen and epitope spectrum were comparable between the two groups, but the prevalence of circulating anti-α3(IV)NC1 IgG1 (67% vs 97%, P = .01) and IgG3 (67% vs 97%, P = .01) were lower in patients with IgAN.

Conclusions: Concurrent IgAN was not rare in anti-GBM disease. Patients showed milder kidney lesions and better recovery after immunosuppressive therapies. This might be partly explained by lower prevalence of anti-GBM IgG1 and IgG3 in these patients.

Keywords: IgA nephropathy; anti-glomerular basement membrane disease; antigen; antigen-specific IgA; epitope.

PubMed Disclaimer

Conflict of interest statement

Nothing to disclose.

Figures

Graphical Abstract
Graphical Abstract
Figure 1:
Figure 1:
The flowchart of patient recruitment.
Figure 2:
Figure 2:
Kaplan-Meier analysis for kidney survival compared between anti-GBM patients with and without IgA nephropathy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cui Z, Zhao MH. Advances in human antiglomerular basement membrane disease. Nat Rev Nephrol 2011;7:697–705. 10.1038/nrneph.2011.89. - DOI - PubMed
    1. Saus J, Wieslander J, Langeveld JPet al. . Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J Biol Chem 1988;263:13374–80. 10.1016/S0021-9258(18)37714-7. - DOI - PubMed
    1. Netzer KO, Leinonen A, Boutaud Aet al. . The goodpasture autoantigen. Mapping the major conformational epitope(s) of alpha3(IV) collagen to residues 17-31 and 127-141 of the NC1 domain. J Biol Chem 1999;274:11267–74. 10.1074/jbc.274.16.11267. - DOI - PubMed
    1. Borza DB, Netzer KO, Leinonen Aet al. . The goodpasture autoantigen. Identification of multiple cryptic epitopes on the NC1 domain of the alpha3(IV) collagen chain. J Biol Chem 2000;275:6030–7. 10.1074/jbc.275.8.6030. - DOI - PubMed
    1. Pedchenko V, Bondar O, Fogo ABet al. . Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 2010;363:343–54. 10.1056/NEJMoa0910500. - DOI - PMC - PubMed